Scanner DailyTickers — Monday, June 29, 2026

EXC is the highest-conviction setup with score 91 — the best in the scan. PE forward 15.6x is deep value for a regulated utility with 3.6% dividend yield (highest in scan). Above all EMAs: EMA20 $46.77, EMA50 $45.39, EMA200 $42.83 with RSI 61.9 in healthy momentum. Extension 1.34% from EMA20 leaves significant upside headroom. ATR% 1.9% = low volatility ideal for defensive H15 hold. As a regulated utility, EXC has zero correlation with the tech selloff and benefits from flight-to-quality flows (gold +1.06%, yields declining). Exelon’s regulated utility model provides earnings visibility and dividend stability — the exact profile that outperforms in sustained ERO. TP1 at $50.20 is 5.9% upside with only 3.0% downside to stop.

VTRS offers the deepest value in the entire scan at PE forward 6.1x with a 3.0% dividend yield. The stock has been steadily recovering since the Mylan-Upjohn merger integration completed — above all EMAs with RSI 56.2 in early momentum. Extension 1.78% from EMA20 provides comfortable entry. ATR% 2.9% is moderate. The generic pharma business model is naturally defensive: drug demand is inelastic, and VTRS benefits from patent cliffs at brand-name competitors. In ERO, cheap healthcare with yield outperforms. The Russell reconstitution Monday could provide additional buying pressure as index funds rebalance. TP1 at $17.80 is 9.0% upside with 4.5% downside to stop — strong 2:1 R/R.

XLU provides broad utilities sector exposure with the lowest volatility in the scan (ATR% 1.5%). Above all EMAs with RSI 63.8 — strongest momentum reading among the ETF picks. As a sector ETF, XLU eliminates single-stock regulatory risk while capturing the flight-to-quality yield premium that dominates in sustained ERO. Gold surging +1.06% and yields declining confirm the defensive rotation thesis. XLU pairs naturally with EXC (#1) for a utilities overweight — their correlation is structural (EXC is a constituent) but XLU diversifies across 30+ utility names. TP1 at $49.00 is 6.1% upside with 3.0% downside to stop.

NVS returns as the EU healthcare anchor for the 3rd consecutive session, validating the setup’s strength. PE forward 15.6x offers compelling value vs US pharma peers (LLY 25x, JNJ 19x). Above all EMAs: EMA20 $150.61, EMA50 $150.03, EMA200 $141.95 — clean bullish stack. RSI 60.2 in momentum zone, extension 2.91% (under the 3% A+ gate). Dividend 3.1% provides yield floor. The $1.9B Antares Therapeutics oncology acquisition + Kisqali/Entresto franchise are growth catalysts. Beta ~0.5 makes this ideal for ERO. Sharia compliant — pharmaceutical sector with low debt-to-mcap ratio. Geographic diversification from US-centric picks. ATR% 1.9% = low vol.

TIGO provides EU geographic diversification in a sector (telecom) uncorrelated with the tech selloff. PE forward 12.5x is compelling value. Dividend 3.4% provides yield. Above EMA20 with RSI 55.6 in early momentum — not over-extended. The wider stop ($83.50, 6.2% below entry) reflects ATR% 4.2%, but the R/R remains 1:2.0 with TP1 at $100 (12.4% upside). Millicom’s LatAm mobile/broadband footprint benefits from emerging market digitization tailwinds independent of US/EU macro. The stock’s low correlation with US utilities and healthcare provides genuine portfolio diversification. The Goldman Sachs fiber-optic investment thesis supports TIGO’s infrastructure value.

SBUX offers a consumer turnaround play at a slightly adjusted entry ($104 vs close $104.60) to bring the EMA20 extension within the 3% A+ gate. Above all EMAs with RSI 61.0 in momentum zone. The Brian Niccol CEO turnaround narrative (from Chipotle) is driving investor enthusiasm — operational improvements in store efficiency, menu innovation, and China recovery. ATR% 2.4% is moderate. Dividend 2.4%. Despite the elevated PE (34.7x), the turnaround premium is justified by accelerating same-store sales growth. The $100 stop provides a clean level below the EMA50 support. Consumer confidence data Tuesday is a direct catalyst for SBUX thesis validation.

ALGN offers healthcare growth at a value price (PE forward 14.4x) in the medical devices subsector. Above EMA20 with RSI 55.0 in early momentum. Align Technology dominates the clear aligner market (Invisalign) with ~80% market share in the premium segment. The stock has been recovering from its 2025 selloff, now above all key moving averages. The wider stop ($167.50, 5.9% below entry) reflects ATR% 4.0%, but the R/R remains 2:1 with TP1 at $199 (11.8% upside). Sharia compliant — medical device company with low debt-to-mcap. The Russell reconstitution Monday could provide additional index-tracking demand. Consumer confidence Tuesday is a secondary catalyst (discretionary dental spending correlation).

HON provides quality industrials exposure at PE 20.3x with a 2.1% dividend yield. Above all EMAs with RSI 58.0 in comfortable momentum. Extension 3.07% is marginally above the 3% A+ gate (capped at grade A for this metric). Honeywell’s diversified business (aerospace, building tech, performance materials, safety & productivity) provides multiple revenue streams uncorrelated with tech. ATR% 3.0% is moderate. The planned 3-way company split (Automation, Aerospace, Advanced Materials) is a catalyst for value unlock. ISM Manufacturing PMI Wednesday is a direct catalyst — strong reading validates the industrials rotation. TP1 at $252 is 8.6% upside with 4.3% downside to stop.

PCAR offers quality cyclical exposure at PE 17.8x in the heavy truck manufacturing sector. Above EMA20 with RSI 56.4 in early momentum. PACCAR (Kenworth, Peterbilt, DAF) benefits from the US infrastructure investment cycle and fleet replacement demand. ATR% 2.8% is moderate. The stock provides diversification from the utility/healthcare bias in the portfolio. TP1 at $130.50 is 8.3% upside with 4.1% downside to stop. ISM Manufacturing PMI Wednesday is a direct catalyst for PCAR — strong truck orders correlate with manufacturing expansion. Correlation with HON at 0.52 is moderate, reflecting shared industrials exposure without being redundant.

EWJ returns as the APAC geographic diversifier, this time offering a post-pullback entry after the Nikkei −4.15% session. The pullback brings RSI to 50.4 — exactly at the momentum/neutral boundary. Above EMA20 ($93.12) but price now sits right at support rather than extended. Extension near zero = ideal entry timing. Japan’s structural tailwinds remain intact: weak yen boosting exports, TSE governance reforms driving buybacks, BOJ normalization attracting institutional flows. The −4.15% move appears technical (profit-taking after +4.61% the prior session) rather than fundamental. ATR% 1.8% is low. TP1 at $99 is 6.5% upside with 3.2% downside to stop. The diversification benefit is significant: avg correlation 0.17 with other picks.